IsoRay, Inc. Reports Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
IsoRay (ISR) Announces Publication of Positive Cesium-131 Data as Lung Cancer Treatment
May 20, 2015 8:19 AM EDTIsoRay (NYSE: ISR) announced the on-line publication of the first major peer reviewed study showing improved results using IsoRay's Cesium-131 seeds in the treatment of lung cancer.
IsoRay CEO Dwight Babcock commented, "We are extremely excited to have our Cesium-131 isotope seeds and mesh used in the treatment of non-small cell lung cancers with such outstanding patient outcomes. Notable physicians, including the authors of this study, are seeking... More
Maxim Still Bullish on IsoRay (ISR) Following Q1 Results; More Physicians Adopting Cesium-131
May 18, 2015 2:51 PM EDTMaxim Group affirms IsoRay (NYSE: ISR) with a Buy rating and $5 price target after the company reported reported Q3 EPS of ($0.02) with revenue of $1.16, versus EPS of ($0.05) and revenue of $1.13 million reported in the same period last year.
Analyst Jason Kolbert noted,... More
IsoRay (ISR) Reports Q3 Loss of $0.02/Share
May 18, 2015 8:47 AM EDTIsoRay (NYSE: ISR) reported Q3 EPS of ($0.02), versus ($0.05) reported last year. Revenue for the quarter came in at $1.16 million, versus $1.13 million reported last year.
For earnings history and earnings-related data on IsoRay (ISR) click here.
... More